ImaRx and Philips to collaborate on treatment for ischemic stroke

Under the agreement, Philips’ medical systems division will provide ultrasound devices and technical assistance to ImaRx during laboratory and preclinical studies. The objective of the collaboration is to determine the optimal ultrasound parameters to use with ImaRx’s proprietary MRX-801 microbubble technology. The agreement includes a mutual exclusivity clause during the term of the collaboration. Following completion of the research program, Philips and ImaRx will have an exclusive negotiation period to discuss future development and commercialization.

Anne LeGrand, senior vice president and general manager, Ultrasound, for Philips Medical Systems, said: “There is a tremendous need for new ways to treat ischemic stroke patients. Philips recognizes the promise of microbubble therapies, and we are pleased to play a role in helping ImaRx advance this important potential treatment. The effort is perfectly aligned with our focus on improving patient care.”

Bradford Zakes, president and CEO of ImaRx, said: “This research collaboration represents a significant step forward for ImaRx’s SonoLysis program. By working closely with Philips Medical Systems, we are incorporating the leading ultrasound technology and expertise into the early stages of product development, which strengthens our position as we move further through our clinical trials.”